BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17452893)

  • 1. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk.
    Cransberg K; Cornelissen M; Lilien M; Van Hoeck K; Davin JC; Nauta J
    Transplantation; 2007 Apr; 83(8):1041-7. PubMed ID: 17452893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
    Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
    J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
    Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.
    Le Meur Y; Thierry A; Glowacki F; Rerolle JP; Garrigue V; Ouali N; Heng AE; Delahousse M; Albano L; Lang P; Couzi L; Jaureguy M; Lebranchu Y; Mousson C; Glotz D; Kessler M; Vrtovsnik F; Rouanet S; Tagieva N; Kamar N
    Transplantation; 2011 Dec; 92(11):1244-51. PubMed ID: 22067312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.
    Schnuelle P; van der Heide JH; Tegzess A; Verburgh CA; Paul LC; van der Woude FJ; de Fijter JW
    J Am Soc Nephrol; 2002 Feb; 13(2):536-543. PubMed ID: 11805185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
    Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis.
    Benz K; Plank C; Griebel M; Montoya C; Dötsch J; Klare B
    Pediatr Transplant; 2006 May; 10(3):331-6. PubMed ID: 16677357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
    Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial.
    Höcker B; Weber LT; Bunchman T; Rashford M; Tönshoff B;
    Pediatr Transplant; 2005 Aug; 9(4):504-11. PubMed ID: 16048604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.
    Abramowicz D; Manas D; Lao M; Vanrenterghem Y; Del Castillo D; Wijngaard P; Fung S;
    Transplantation; 2002 Dec; 74(12):1725-34. PubMed ID: 12499889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years.
    Jungraithmayr T; Staskewitz A; Kirste G; Böswald M; Bulla M; Burghard R; Dippell J; Greiner C; Helmchen U; Klare B; Klaus G; Leichter HE; Mihatsch MJ; Michalk DV; Misselwitz J; Plank C; Querfeld U; Weber LT; Wiesel M; Tönshoff B; Zimmerhackl LB;
    Transplantation; 2003 Feb; 75(4):454-61. PubMed ID: 12605109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial.
    Åsberg A; Apeland T; Reisaeter AV; Foss A; Leivestad T; Heldal K; Thorud LO; Eriksen BO; Hartmann A;
    Clin Transplant; 2013; 27(2):E151-6. PubMed ID: 23351013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.